NOAEL Studies
Cosmetic Ingredient
Tyrosine NOAEL Studies
INCI: TYROSINE
CAS: 60-18-4 (L-Tyrosine); 556-03-6 (DL-Tyrosine)
Raw No Observed Adverse Effect Level endpoint records grouped by source. This page does not render calculated Margin of Safety values.
ECHA_REACH_reach_study_results_dossiers_23-05-2023.zip 6 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| ECHA_REACH_reach_study_results_dossiers_23-05-2023.zip | NOAEL | 200 | mg/kg bw/day | rat | oral: gavage | - | sub-chronic toxicity: oral | dossier=3f989a82-cc2f-4cf4-ab4c-2a935c2ec3fb.i6z; document=4300a4f8-bda7-4adf-a91c-7150373637a9_3f989a82-cc2f-4cf4-ab4c-2a935c2ec3fb.i6d; document_key=4300a4f8-bda7-4adf-a91c-7150373637a9/3f989a82-cc2f-4cf4-ab4c-2a935c2ec3fb; document_subtype=RepeatedDoseToxicityOral; literature=Name=Unnamed; ReferenceYear=2016; basis=histopathology: non-neoplastic; key_result=false; entry_uuid=dc174ed8-e990-4606-b8b4-bd419a93f492 |
| ECHA_REACH_reach_study_results_dossiers_23-05-2023.zip | NOAEL | 600 | mg/kg bw/day | rat | oral: gavage | - | sub-chronic toxicity: oral | dossier=3f989a82-cc2f-4cf4-ab4c-2a935c2ec3fb.i6z; document=4300a4f8-bda7-4adf-a91c-7150373637a9_3f989a82-cc2f-4cf4-ab4c-2a935c2ec3fb.i6d; document_key=4300a4f8-bda7-4adf-a91c-7150373637a9/3f989a82-cc2f-4cf4-ab4c-2a935c2ec3fb; document_subtype=RepeatedDoseToxicityOral; literature=Name=Unnamed; ReferenceYear=2016; basis=histopathology: non-neoplastic; key_result=false; entry_uuid=32aa4c3d-65dc-401e-ba0a-038f32f4a5dd |
| ECHA_REACH_reach_study_results_dossiers_23-05-2023.zip | NOAEL | 200 | mg/kg bw/day | rat | oral: gavage | - | sub-chronic toxicity: oral | dossier=3f989a82-cc2f-4cf4-ab4c-2a935c2ec3fb.i6z; document=4300a4f8-bda7-4adf-a91c-7150373637a9_3f989a82-cc2f-4cf4-ab4c-2a935c2ec3fb.i6d; document_key=4300a4f8-bda7-4adf-a91c-7150373637a9/3f989a82-cc2f-4cf4-ab4c-2a935c2ec3fb; document_subtype=RepeatedDoseToxicityOral; literature=Name=Unnamed; ReferenceYear=2016; basis=histopathology: non-neoplastic; key_result=false; entry_uuid=dc174ed8-e990-4606-b8b4-bd419a93f492 |
| ECHA_REACH_reach_study_results_dossiers_23-05-2023.zip | NOAEL | 600 | mg/kg bw/day | rat | oral: gavage | - | sub-chronic toxicity: oral | dossier=3f989a82-cc2f-4cf4-ab4c-2a935c2ec3fb.i6z; document=4300a4f8-bda7-4adf-a91c-7150373637a9_3f989a82-cc2f-4cf4-ab4c-2a935c2ec3fb.i6d; document_key=4300a4f8-bda7-4adf-a91c-7150373637a9/3f989a82-cc2f-4cf4-ab4c-2a935c2ec3fb; document_subtype=RepeatedDoseToxicityOral; literature=Name=Unnamed; ReferenceYear=2016; basis=histopathology: non-neoplastic; key_result=false; entry_uuid=32aa4c3d-65dc-401e-ba0a-038f32f4a5dd |
| ECHA_REACH_reach_study_results_dossiers_23-05-2023.zip | NOAEL | 200 | mg/kg bw/day | rat | oral: gavage | - | sub-chronic toxicity: oral | dossier=3f989a82-cc2f-4cf4-ab4c-2a935c2ec3fb.i6z; document=4300a4f8-bda7-4adf-a91c-7150373637a9_3f989a82-cc2f-4cf4-ab4c-2a935c2ec3fb.i6d; document_key=4300a4f8-bda7-4adf-a91c-7150373637a9/3f989a82-cc2f-4cf4-ab4c-2a935c2ec3fb; document_subtype=RepeatedDoseToxicityOral; literature=Name=Unnamed; ReferenceYear=2016; basis=histopathology: non-neoplastic; key_result=false; entry_uuid=dc174ed8-e990-4606-b8b4-bd419a93f492 |
| ECHA_REACH_reach_study_results_dossiers_23-05-2023.zip | NOAEL | 600 | mg/kg bw/day | rat | oral: gavage | - | sub-chronic toxicity: oral | dossier=3f989a82-cc2f-4cf4-ab4c-2a935c2ec3fb.i6z; document=4300a4f8-bda7-4adf-a91c-7150373637a9_3f989a82-cc2f-4cf4-ab4c-2a935c2ec3fb.i6d; document_key=4300a4f8-bda7-4adf-a91c-7150373637a9/3f989a82-cc2f-4cf4-ab4c-2a935c2ec3fb; document_subtype=RepeatedDoseToxicityOral; literature=Name=Unnamed; ReferenceYear=2016; basis=histopathology: non-neoplastic; key_result=false; entry_uuid=32aa4c3d-65dc-401e-ba0a-038f32f4a5dd |